Acticor Biotech SA
PAR:ALACT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
C
|
Canadian Net Real Estate Investment Trust
XTSX:NET.UN
|
CA |
|
Capital Financial Indonesia Tbk PT
IDX:CASA
|
ID |
|
Kriti Industries (India) Limited
NSE:KRITI
|
IN |
|
JK Paper Ltd
NSE:JKPAPER
|
IN |
|
Essential Energy Services Ltd
TSX:ESN
|
CA |
|
X
|
Xero Ltd
OTC:XROLF
|
NZ |
|
bet-at-home.com AG
XETRA:ACX
|
DE |
|
V
|
Vision Sensing Acquisition Corp
NASDAQ:VSAC
|
US |
|
Protagonist Therapeutics Inc
NASDAQ:PTGX
|
US |
|
D
|
Dar Global PLC
LSE:DAR
|
UK |
|
Seadrill Ltd
OSE:SDRL
|
BM |
Acticor Biotech SA
Research & Development
Acticor Biotech SA
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Acticor Biotech SA
PAR:ALACT
|
Research & Development
-€14.2m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Valneva SE
PAR:VLA
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Research & Development
-€40.6m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
5%
|
CAGR 10-Years
N/A
|
|
|
Inventiva SA
PAR:IVA
|
Research & Development
-€86.2m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
N/A
|
|
|
DBV Technologies SA
PAR:DBV
|
Research & Development
-$95.9m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
9%
|
CAGR 10-Years
-16%
|
|
|
Abivax SA
PAR:ABVX
|
Research & Development
-€199.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Acticor Biotech SA
Glance View
Acticor Biotech SAS engages in the research and development of an antithrombotic agent for the treatment of the acute thrombotic diseases. The company is headquartered in Paris, Ile-De-France and currently employs 22 full-time employees. The company went IPO on 2021-11-01. The firm is a clinical stage biopharmaceutical company, a spin-off from INSERM (French National Institute of Health and Medical Research), specialized in the research and development of medicines for the treatment of thrombotic diseases, in particular acute ischemic strokes and pulmonary embolisms. The group has one product in Phase II clinical development (Glenzocimab) and its products in pipeline are ACTIMIS, GARDEN, ACTISAVE and GREEN. Its partnering companies are Ouest Valorisation, Genopole, Medicine and Inserm.
See Also
What is Acticor Biotech SA's Research & Development?
Research & Development
-14.2m
EUR
Based on the financial report for Dec 31, 2023, Acticor Biotech SA's Research & Development amounts to -14.2m EUR.
What is Acticor Biotech SA's Research & Development growth rate?
Research & Development CAGR 3Y
-25%
Over the last year, the Research & Development growth was -1%. The average annual Research & Development growth rates for Acticor Biotech SA have been -25% over the past three years .
